CARB-X Application Round #3 goes live!

Dear All:

The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary:

  • Round 1:
    • Submission window for Expressions of Interest: 22-29 March 2018
    • Scope: Restricted to new classes of direct-acting small molecule and large molecule antibacterials that have potential to cover the top 6 Gram-negative pathogen groups from the WHO and CDC priority listsA. baumannii (carbapenem-R), P. aeruginosa (carbapenem-R), Enterobacteriaceae (carbapenem-R and/or 3rd-gen ceph-R), Salmonellae spp. (fluoroquinolone-R), N. gonorrhoeae (3rd-gen ceph-R, fluoroquinolone-R), and Shigella spp. (fluoroquinolone-R).
  • Round 2:
    • Submission window for Expressions of Interest: 1-8 June 2018
    • Scope: Both direct- and indirect-acting therapeutics as well as vaccines, diagnostics and devices that meet certain criteria.
    • In terms of therapeutics, both novel and known classes are acceptable.

The very tight focus of Round #1 feels right to me … we really need to push hard at a global level on the creation of entirely novel classes of direct-acting agents. These will be rare but they are needed.

The scope of Round #2 is then broad and roughly comparable to the scope of prior CARB-X funding rounds.

With an announced portfolio of more than 20 projects and its search for both new accelerators and new staff, CARB-X continues to lead the charge against AMR. Exciting times! 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

EPA (part 2, streptomycin!) / $104m ARPA-H AMR project

Dear All (OK, so now it’s 5 newsletters in as many days … exciting times … can’t keep up!), Two follow-up items today. First, yesterday’s newsletter about EPA’s concept note regarding AMR risks of pesticides prompted one of your fellow readers to remind me about this lawsuit filed with the U.S. Court of Appeals, Ninth Circuit: Case

BARDA Medical Countermeasures BAA: Substantial updates

Dear All (and yes, back-to-back newsletters … lots of action this week!): BARDA have today released a new version of their long-running BAA (Broad Agency Announcement, formerly BAA-18-100-SOL-00003) that seeks medical countermeasures (MCMs) for chemical, biological, radiological, and nuclear (CBRN) threats, pandemic influenza, and emerging infectious diseases. The new BAA is BAA-23-100-SOL-00004 and has been completely reorganized and

Appropriate duration of antimicrobial dosing in food animal care

Dear All,  I’ve watched with interest the way that FDA’s CVM (Center for Veterinary Medicine) has been working steadily with the veterinary community as a whole to reduce antibiotic resistance pressure by improving the way antibiotics are used in animal care. The titles of these prior newsletters give you a feel for some aspects of

Scroll to Top